Stock Track | Ascletis Pharma Soars 5.07% on Promising Weight Loss Drug Combination Results

Stock Track

Aug 18

Ascletis Pharma (HKG:1672) saw its stock price soar by 5.07% in Monday's trading session following the announcement of encouraging preclinical results for its novel weight loss drug combination.

The company reported that a combination of its experimental drugs ASC47 and ASC31 demonstrated significantly greater weight loss compared to ASC47 plus tirzepatide in an animal model of obesity. The combination of low-dose ASC47 with ASC31 resulted in a 44.8% reduction in body weight, outperforming the 38.1% reduction achieved by ASC47 plus tirzepatide after 14 days of treatment in diet-induced obese mice.

Dr. Wu Jinzi, Founder, Chairman of the Board and Chief Executive Officer of Ascletis, expressed optimism about the results, stating, "Our novel GLP-1R/GIPR dual receptor agonist peptide ASC31 combined with THRβ agonist ASC47 demonstrated excellent weight loss effects in this animal model. This new therapy shows significant differentiation potential compared to marketed weight loss drugs and other investigational candidate drugs." The company is building a robust pipeline of potential obesity therapies covering both small molecules and peptides, positioning itself strongly in the competitive weight loss drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1101317499"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101317499\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101317499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101317499","market":"nz","top_or_hot":-1,"title":"Stock Track | Ascletis Pharma Soars 5.07% on Promising Weight Loss Drug Combination Results","media":"Stock Track","content":"<p>Ascletis Pharma (HKG:1672) saw its stock price soar by 5.07% in Monday's trading session following the announcement of encouraging preclinical results for its novel weight loss drug combination.</p>\n\n<p>The company reported that a combination of its experimental drugs ASC47 and ASC31 demonstrated significantly greater weight loss compared to ASC47 plus tirzepatide in an animal model of obesity. The combination of low-dose ASC47 with ASC31 resulted in a 44.8% reduction in body weight, outperforming the 38.1% reduction achieved by ASC47 plus tirzepatide after 14 days of treatment in diet-induced obese mice.</p>\n\n<p>Dr. Wu Jinzi, Founder, Chairman of the Board and Chief Executive Officer of Ascletis, expressed optimism about the results, stating, \"Our novel GLP-1R/GIPR dual receptor agonist peptide ASC31 combined with THRβ agonist ASC47 demonstrated excellent weight loss effects in this animal model. This new therapy shows significant differentiation potential compared to marketed weight loss drugs and other investigational candidate drugs.\" The company is building a robust pipeline of potential obesity therapies covering both small molecules and peptides, positioning itself strongly in the competitive weight loss drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ascletis Pharma Soars 5.07% on Promising Weight Loss Drug Combination Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ascletis Pharma Soars 5.07% on Promising Weight Loss Drug Combination Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-18 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma (HKG:1672) saw its stock price soar by 5.07% in Monday's trading session following the announcement of encouraging preclinical results for its novel weight loss drug combination.</p>\n\n<p>The company reported that a combination of its experimental drugs ASC47 and ASC31 demonstrated significantly greater weight loss compared to ASC47 plus tirzepatide in an animal model of obesity. The combination of low-dose ASC47 with ASC31 resulted in a 44.8% reduction in body weight, outperforming the 38.1% reduction achieved by ASC47 plus tirzepatide after 14 days of treatment in diet-induced obese mice.</p>\n\n<p>Dr. Wu Jinzi, Founder, Chairman of the Board and Chief Executive Officer of Ascletis, expressed optimism about the results, stating, \"Our novel GLP-1R/GIPR dual receptor agonist peptide ASC31 combined with THRβ agonist ASC47 demonstrated excellent weight loss effects in this animal model. This new therapy shows significant differentiation potential compared to marketed weight loss drugs and other investigational candidate drugs.\" The company is building a robust pipeline of potential obesity therapies covering both small molecules and peptides, positioning itself strongly in the competitive weight loss drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1101317499","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101317499","pubTimestamp":1755484604,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ascletis Pharma (HKG:1672) saw its stock price soar by 5.07% in Monday's trading session following the announcement of encouraging preclinical results for its novel weight loss drug combination.  The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"个股追踪|歌礼制药大涨5.07%减肥药组合结果看好","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma (HKG:1672) saw its stock price soar by 5.07% in Monday's trading session following the announcement of encouraging preclinical results for its novel weight loss drug combination.\nThe company reported that a combination of its experimental drugs ASC47 and ASC31 demonstrated significantly greater weight loss compared to ASC47 plus tirzepatide in an animal model of obesity. The combination of low-dose ASC47 with ASC31 resulted in a 44.8% reduction in body weight, outperforming the 38.1% reduction achieved by ASC47 plus tirzepatide after 14 days of treatment in diet-induced obese mice.\nDr. Wu Jinzi, Founder, Chairman of the Board and Chief Executive Officer of Ascletis, expressed optimism about the results, stating, \"Our novel GLP-1R/GIPR dual receptor agonist peptide ASC31 combined with THRβ agonist ASC47 demonstrated excellent weight loss effects in this animal model. This new therapy shows significant differentiation potential compared to marketed weight loss drugs and other investigational candidate drugs.\" The company is building a robust pipeline of potential obesity therapies covering both small molecules and peptides, positioning itself strongly in the competitive weight loss drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}